Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17472947 | 0.79 | MMP14 (0.55) | L3MBTL1APPMMP14 | |
| SCHEMBL2549477 | 0.78 | APP (0.42) | APPHTR2AHTR2CSLC6A4 | |
| SCHEMBL29602667 | 0.77 | GBA1 (0.42) | L3MBTL1APPHTR2CSLC6A4NPC1 | |
| SCHEMBL9632043 | 0.77 | TPMT (0.40) | L3MBTL1TPMTAPPCA12CA9 | |
| SCHEMBL20004504 | 0.76 | L3MBTL1 (0.46) | L3MBTL1APPNPC1RAB9A | |
| SCHEMBL23275292 | 0.75 | RAB9A (0.50) | NPC1RAB9ACA12CA9 | |
| SCHEMBL2097717 | 0.74 | TPMT (0.44) | TPMTAPPNPC1RAB9A | |
| SCHEMBL19086438 | 0.74 | POLB (0.37) | TPMTHTR2AHTR2CNPC1RAB9A | |
| SCHEMBL19086409 | 0.73 | PDE1A (0.50) | — | |
| SCHEMBL29426388 | 0.72 | APP (0.41) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986896-B1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | L3MBTL1 2578/4885TPMT 2122/4885APP 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.